Cefalexin (1st Gen) Capsules and tablets

Cefalexin (1st Gen) Capsules and tablets

Form: Oral Capsules and Tablets

Strength: 250 mg, 500 mg

Reference Brands: Keflex(US & EU)

Category: Antibiotics

Cephalexin oral capsules and tablets are approved across the EU and US for treating bacterial infections such as skin, respiratory, and urinary tract infections. In the EU, brands like Keflex and generic formulations are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data, with generic options readily available. Both regions require detailed dossiers including clinical trial results, quality control, and pharmacovigilance plans for initial approval and safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access, ensuring adherence to European and US standards for safe, effective use.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Fosfomycin IV

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.